Table 2.
Literature curated test set for mouse LD50 predictions. For molecule structures and predictions for each individual machine learning algorithm please see the Supplemental data table.
| Molecule name | Reference | Route of Administration | EPA Category | Qualifier | LD50 (mg/kg) | Average LD50 Prediction with regression models for route of admin (mg/kg) | Average LD50 prediction with classification models | Applicability Domain for classification models |
|---|---|---|---|---|---|---|---|---|
| Gambierone | 57 | IP | = | 2 | 12.86 | - | - | |
| IMB-0523 | 58 | IP | = | 448 | 202.09 | - | - | |
| 2 | 59 | IV | = | 42 | 21.93 | - | - | |
| Harmine | 60 | IV | = | 27 | 27.73 | - | - | |
| 1 | 59 | IV | = | 26 | 25.37 | - | - | |
| 3 | 59 | IV | = | 24 | 27.16 | - | - | |
| Mitomycin C | 61 | Oral | I | < | 3 | 551.25 | 0 | 0.30 |
| 6 | 61 | Oral | I | < | 20 | 668.16 | 1 | 0.50 |
| Gelsenicine * | 62 | Oral | I | = | 1 | 360.86 | 1 | 0.43 |
| Dihydroanatoxin-a | 63 | Oral | I | = | 3 | 591.64 | 1 | 0.28 |
| Anatoxin-a | 63 | Oral | I | = | 11 | 709.03 | 0 | 0.24 |
| Dechloro-CPF * | 64 | Oral | I | = | 45 | 494.41 | 0 | 0.19 |
| 19l | 65 | Oral | III | = | 944 | 685.47 | 0 | 0.35 |
| 19m | 65 | Oral | III | = | 962 | 753.87 | 0 | 0.40 |
| 19k | 65 | Oral | III | = | 1001 | 607.87 | 0 | 0.37 |
| 19n | 65 | Oral | III | = | 1148 | 635.59 | 0 | 0.41 |
| 19j | 65 | Oral | III | = | 1155 | 712.26 | 0 | 0.42 |
| 20l | 65 | Oral | III | = | 1158 | 626.8 | 0 | 0.41 |
| 19h | 65 | Oral | III | = | 1176 | 740.48 | 0 | 0.44 |
| 19p | 65 | Oral | III | = | 1189 | 573.93 | 0 | 0.33 |
| 20b | 65 | Oral | III | = | 1203 | 795.03 | 0 | 0.45 |
| 20d | 65 | Oral | III | = | 1203 | 564.81 | 0 | 0.45 |
| 20f | 65 | Oral | III | = | 1243 | 868.19 | 0 | 0.46 |
| 20i | 65 | Oral | III | = | 1352 | 615.40 | 0 | 0.45 |
| 20n | 65 | Oral | III | = | 1386 | 599.58 | 0 | 0.43 |
| 20p | 65 | Oral | III | = | 1386 | 603.34 | 0 | 0.43 |
| 4k | 66 | Oral | III | = | 1565 | 509.90 | 0 | 0.38 |
| 4l | 66 | Oral | III | = | 1590 | 555.66 | 0 | 0.55 |
| 4a | 66 | Oral | III | = | 1625 | 554.75 | 0 | 0.38 |
| 4b | 66 | Oral | III | = | 1625 | 528.96 | 0 | 0.54 |
| 4d | 66 | Oral | III | = | 1634 | 521.79 | 0 | 0.52 |
| 4m | 66 | Oral | III | = | 1650 | 542.42 | 0 | 0.36 |
| 4n | 66 | Oral | III | = | 1700 | 564.55 | 0 | 0.38 |
| 4i | 66 | Oral | III | = | 1720 | 631.95 | 0 | 0.25 |
| 4c | 66 | Oral | III | = | 1728 | 574.29 | 0 | 0.52 |
| 4f | 66 | Oral | III | = | 1790 | 689.81 | 0 | 0.33 |
| 4h | 66 | Oral | III | = | 1790 | 662.78 | 0 | 0.38 |
| 4e | 66 | Oral | III | = | 1820 | 759.07 | 0 | 0.35 |
| 4g | 66 | Oral | III | = | 1820 | 644.21 | 0 | 0.33 |
| 4j | 66 | Oral | III | = | 1840 | 492.15 | 0 | 0.25 |
| Nevirapine | 67 | Oral | III | = | 2154 | 560.35 | 0 | 0.46 |
| Permethrin | 68 | Oral | IV | > | 500 | 693.57 | 0 | 0.30 |
| DCA-O | 68 | Oral | IV | > | 500 | 746.64 | 0 | 0.32 |
| DCA-01 | 68 | Oral | IV | > | 500 | 601.33 | 0 | 0.28 |
| DCA-11 | 68 | Oral | IV | > | 500 | 719.26 | 0 | 0.25 |
| 29 | 69 | Oral | IV | > | 500 | 420.49 | 1 | 0.25 |
| Deltamethrin | 68 | Oral | IV | > | 500 | 564.69 | 1 | 0.27 |
| F8 | 70 | Oral | IV | > | 1000 | 777.45 | 0 | 0.50 |
| iodophenyl 5-methyl-3-(p-tolyl)-1H-pyrazole-1-sulfonate | 71 | Oral | IV | > | 2000 | 666.38 | 0 | 0.55 |
| 2-chlorophenyl 5-methyl-3-(p-tolyl)-1H-pyrazole-1-sulfonate | 71 | Oral | IV | > | 2000 | 766.65 | 0 | 0.55 |
| Jaranol | 72 | Oral | IV | > | 2000 | 719.96 | 0 | 0.42 |
| (−)-Carveol | 73 | Oral | IV | > | 2500 | 464.85 | 1 | 0.26 |
| Estragole | 74 | Oral | IV | > | 2500 | 500.88 | 1 | 0.26 |
sex difference averaged